DK2344471T3 - 7-piperidinalkyl-3,4-dihydroquinolon-derivat - Google Patents

7-piperidinalkyl-3,4-dihydroquinolon-derivat

Info

Publication number: DK2344471T3
Authority: DK; Denmark
Prior art keywords: piperidinealkyl; dihydroquinolone; derivative; dihydroquinolone derivative
Prior art date: 2008-10-02

Application number

DK09817928.6T

Other languages

English (en)

Inventor

Kosuke Kanuma

Naoki Miyakoshi

Madoka Kawamura

Tsuyoshi Shibata

Original Assignee

Taisho Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-02

Filing date

2009-09-30

Publication date

2013-10-07

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42073652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2344471(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-09-30 Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd

2013-10-07 Application granted granted Critical

2013-10-07 Publication of DK2344471T3 publication Critical patent/DK2344471T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Obesity (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Addiction (AREA)
Reproductive Health (AREA)
Psychology (AREA)
Emergency Medicine (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Anesthesiology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Gynecology & Obstetrics (AREA)
Nutrition Science (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

DK09817928.6T 2008-10-02 2009-09-30 7-piperidinalkyl-3,4-dihydroquinolon-derivat DK2344471T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2008257072		2008-10-02
PCT/JP2009/067441 WO2010038901A1 (en)	2008-10-02	2009-09-30	7-piperidinoalkyl-3,4-dihydroquinolone derivative

Publications (1)

Publication Number	Publication Date
DK2344471T3 true DK2344471T3 (da)	2013-10-07

Family

ID=42073652

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK09817928.6T DK2344471T3 (da)	2008-10-02	2009-09-30	7-piperidinalkyl-3,4-dihydroquinolon-derivat

Country Status (28)

Country	Link
US (1)	US8461182B2 (da)
EP (1)	EP2344471B1 (da)
JP (1)	JP5541279B2 (da)
KR (1)	KR20110067026A (da)
CN (1)	CN102239159B (da)
AR (1)	AR073727A1 (da)
AU (1)	AU2009300607C1 (da)
BR (1)	BRPI0925343A2 (da)
CA (1)	CA2739513A1 (da)
CL (1)	CL2011000734A1 (da)
CO (1)	CO6321164A2 (da)
CY (1)	CY1114165T1 (da)
DK (1)	DK2344471T3 (da)
ES (1)	ES2424393T3 (da)
HR (1)	HRP20130728T1 (da)
IL (1)	IL212070A (da)
MX (1)	MX2011003500A (da)
MY (1)	MY154337A (da)
NZ (1)	NZ592008A (da)
PE (1)	PE20110410A1 (da)
PL (1)	PL2344471T3 (da)
PT (1)	PT2344471E (da)
RS (1)	RS52964B (da)
RU (1)	RU2498981C2 (da)
SI (1)	SI2344471T1 (da)
UA (1)	UA105187C2 (da)
WO (1)	WO2010038901A1 (da)
ZA (1)	ZA201102315B (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2011219467A (ja) *	2010-03-26	2011-11-04	Taisho Pharmaceutical Co Ltd	７−ピペリジノアルキル−３，４−ジヒドロキノロン誘導体を含有する医薬
AU2011326071A1 (en)	2010-11-08	2013-05-23	Lycera Corporation	N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of RORy activity and the treatment of diseases
US9394315B2 (en)	2012-05-08	2016-07-19	Lycera Corporation	Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
MX367341B (es)	2012-05-08	2019-08-14	Merck Sharp & Dohme	Tetrahidronaftiridina y compuestos biciclicos relacionados para la inhibicion de la actividad de rorgamma y el tratamiento de enfermedades.
EP2968210B1 (en) *	2013-03-12	2024-09-11	Bio-Pharm Solutions Co., Ltd.	Phenyl carbamate compounds for use in preventing or treating pediatric epilesy
WO2015095795A1 (en)	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	TETRAHYDRONAPHTHYRIDINE, BENZOXAZINE, AZA-BENZOXAZINE, AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
WO2015095792A1 (en)	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	Carbamate benzoxaxine propionic acids and acid derivatives for modulation of rorgamma activity and the treatment of disease
WO2015095788A1 (en)	2013-12-20	2015-06-25	Merck Sharp & Dohme Corp.	2-ACYLAMIDOMETHYL AND SULFONYLAMIDOMETHYL BENZOXAZINE CARBAMATES FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
CA2939305A1 (en)	2014-02-27	2015-09-03	Lycera Corporation	Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
CA2947290A1 (en)	2014-05-05	2015-11-12	Lycera Corporation	Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
WO2015171558A2 (en)	2014-05-05	2015-11-12	Lycera Corporation	BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
CA2975997A1 (en)	2015-02-11	2016-08-18	Merck Sharp & Dohme Corp.	Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
JP2018515491A (ja)	2015-05-05	2018-06-14	リセラ・コーポレイションＬｙｃｅｒａＣｏｒｐｏｒａｔｉｏｎ	ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
EP3307738B1 (en)	2015-06-11	2022-04-20	The Regents of the University of Michigan	Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of rory and the treatment of disease
CA3002846A1 (en)	2015-10-27	2017-05-04	Merck Sharp & Dohme Corp.	Substituted bicyclic pyrazole compounds as rorgammat inhibitors and uses thereof
WO2017075182A1 (en)	2015-10-27	2017-05-04	Merck Sharp & Dohme Corp.	Substituted indazole compounds as rorgammat inhibitors and uses thereof
WO2017075185A1 (en)	2015-10-27	2017-05-04	Merck Sharp & Dohme Corp.	Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
RU2743424C2 (ru) *	2016-02-12	2021-02-18	Астеллас Фарма Инк.	Производные тетрагидроизохинолина

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI0850235T1 (en) *	1995-09-15	2000-04-30	Sanofi-Synthelabo	Quinolein-2(1h)-one derivatives as serotonin antagonists
US7544690B2 (en) *	2001-10-01	2009-06-09	Taisho Pharmaceutical Co., Ltd.	MCH receptor antagonists
WO2003035624A1 (en) *	2001-10-25	2003-05-01	Takeda Chemical Industries, Ltd.	Quinoline compound
EP1464335A3 (en) *	2003-03-31	2007-05-09	Taisho Pharmaceutical Co. Ltd.	Quinoline, tetrahydroquinoline and pyrimidine derivatives as mch antagonist
EP1611109A4 (en) *	2003-03-31	2009-06-24	Taisho Pharmaceutical Co Ltd	NOVEL QUINAZOLINE DERIVATIVES AND THEIR THERAPEUTIC USE
US20050209274A1 (en) *	2004-02-26	2005-09-22	Lynch John K	Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor
CN101693695A (zh) *	2004-03-30	2010-04-14	大正制药株式会社	嘧啶衍生物以及与其应用有关的治疗方法
US20080090863A1 (en) *	2004-09-30	2008-04-17	Taisho Pharmaceutical Co., Ltd.	Pyridine Derivatives and Their Use as Medicaments for Treating Diseases Related to Mch Receptor
RU2009117182A (ru) *	2006-10-06	2010-11-20	Тайсо Фармасьютикал Ко., Лтд. (Jp)	Производное 1-нафтилалкилпиперидина

2009
- 2009-09-30 RU RU2011117161/04A patent/RU2498981C2/ru not_active IP Right Cessation
- 2009-09-30 UA UAA201105428A patent/UA105187C2/uk unknown
- 2009-09-30 CN CN200980149091.2A patent/CN102239159B/zh not_active Expired - Fee Related
- 2009-09-30 PT PT98179286T patent/PT2344471E/pt unknown
- 2009-09-30 WO PCT/JP2009/067441 patent/WO2010038901A1/en not_active Ceased
- 2009-09-30 PE PE2011000810A patent/PE20110410A1/es not_active Application Discontinuation
- 2009-09-30 JP JP2011513768A patent/JP5541279B2/ja not_active Expired - Fee Related
- 2009-09-30 ES ES09817928T patent/ES2424393T3/es active Active
- 2009-09-30 BR BRPI0925343-2A patent/BRPI0925343A2/pt not_active IP Right Cessation
- 2009-09-30 RS RS20130370A patent/RS52964B/sr unknown
- 2009-09-30 KR KR1020117007343A patent/KR20110067026A/ko not_active Ceased
- 2009-09-30 US US13/122,281 patent/US8461182B2/en not_active Expired - Fee Related
- 2009-09-30 PL PL09817928T patent/PL2344471T3/pl unknown
- 2009-09-30 MX MX2011003500A patent/MX2011003500A/es active IP Right Grant
- 2009-09-30 EP EP09817928.6A patent/EP2344471B1/en active Active
- 2009-09-30 MY MYPI2011001430A patent/MY154337A/en unknown
- 2009-09-30 NZ NZ592008A patent/NZ592008A/en not_active IP Right Cessation
- 2009-09-30 DK DK09817928.6T patent/DK2344471T3/da active
- 2009-09-30 AU AU2009300607A patent/AU2009300607C1/en not_active Ceased
- 2009-09-30 SI SI200930738T patent/SI2344471T1/sl unknown
- 2009-09-30 CA CA2739513A patent/CA2739513A1/en not_active Abandoned
- 2009-09-30 HR HRP20130728AT patent/HRP20130728T1/hr unknown
- 2009-10-01 AR ARP090103798A patent/AR073727A1/es unknown
2011
- 2011-03-29 ZA ZA2011/02315A patent/ZA201102315B/en unknown
- 2011-03-30 CO CO11038711A patent/CO6321164A2/es active IP Right Grant
- 2011-03-31 IL IL212070A patent/IL212070A/en not_active IP Right Cessation
- 2011-04-01 CL CL2011000734A patent/CL2011000734A1/es unknown
2013
- 2013-07-25 CY CY20131100633T patent/CY1114165T1/el unknown

Also Published As

Publication number	Publication date
PT2344471E (pt)	2013-08-01
SI2344471T1 (sl)	2013-11-29
CN102239159A (zh)	2011-11-09
AU2009300607B2 (en)	2014-02-27
AU2009300607C1 (en)	2014-08-07
CY1114165T1 (el)	2016-08-31
MY154337A (en)	2015-05-29
AU2009300607A1 (en)	2010-04-08
JP2012504549A (ja)	2012-02-23
PE20110410A1 (es)	2011-07-02
JP5541279B2 (ja)	2014-07-09
ZA201102315B (en)	2012-06-27
US8461182B2 (en)	2013-06-11
ES2424393T3 (es)	2013-10-01
IL212070A (en)	2014-07-31
UA105187C2 (uk)	2014-04-25
NZ592008A (en)	2011-12-22
BRPI0925343A2 (pt)	2015-07-28
RU2498981C2 (ru)	2013-11-20
RS52964B (sr)	2014-02-28
WO2010038901A1 (en)	2010-04-08
EP2344471A1 (en)	2011-07-20
CA2739513A1 (en)	2010-04-08
EP2344471A4 (en)	2012-05-30
RU2011117161A (ru)	2012-11-10
US20110178304A1 (en)	2011-07-21
CN102239159B (zh)	2014-06-25
MX2011003500A (es)	2011-05-02
CL2011000734A1 (es)	2011-09-23
PL2344471T3 (pl)	2013-12-31
EP2344471B1 (en)	2013-07-24
HRP20130728T1 (en)	2013-10-11
IL212070A0 (en)	2011-06-30
AR073727A1 (es)	2010-11-24
CO6321164A2 (es)	2011-09-20
KR20110067026A (ko)	2011-06-20
HK1159622A1 (en)	2012-08-03

Publication	Publication Date	Title
FIC20220024I1 (fi)	2022-06-30	Anifrolumabi
FIC20210049I1 (fi)	2021-12-13	Satralitsumabi
NO2021006I1 (no)	2021-02-15	Quofenix, delafloksacin
DK2344471T3 (da)	2013-10-07	7-piperidinalkyl-3,4-dihydroquinolon-derivat
HRP20151058T1 (xx)	2015-12-04	Ariloazol-2-il-cijanoetilamino-spojevi, postupak njihove proizvodnje i postupak njihove uporabe
EP2376493A4 (en)	2012-05-30	DIHYDROPYRIMIDOPYRIMIDINDERIVAT
ATE555107T1 (de)	2012-05-15	2-aza-bicyclo-ä2,2,1-üheptan-derivate
EP2380877A4 (en)	2012-06-27	PYRIDINE-3-CARBONSÄUREAMIDDERIVAT
DK2308877T3 (da)	2014-04-22	Imidazopyridin-2-on-derivater
DK2340021T3 (da)	2012-12-10	Substituerede pyrrolidin-2-carboxamider
EP2258938A4 (en)	2012-09-05	TYPE VEHICLE TO BE PROVIDED
EP2336764A4 (en)	2011-09-28	LIQUID CHROMATOGRAPH
EP2336132A4 (en)	2012-03-21	MORPHOLINPURINDERIVAT
UY33125A (es)	2011-07-29	Diaza-espiro-[5,5]-undecanos
DK2275414T3 (da)	2015-06-22	Cyclopentylacrylamidderivat
DE602008003970D1 (de)	2011-01-27	Strahlstromkalibriersystem
BRPI0917446A2 (pt)	2015-12-22	derivados de acilaminobenzamida.
ATE545635T1 (de)	2012-03-15	Substituierte n-oxidpyrazinderivate
BRPI0906714A2 (pt)	2015-06-30	Derivados de oxazepinopirimidona heteroarilamida substituídos.
DK2442870T3 (da)	2014-06-30	Pyrazinooxazepin-derivater.
ATE534634T1 (de)	2011-12-15	2-phenyl-4-cyclopropyl-pyrimidinderivate
BRPI0912716A2 (pt)	2015-10-13	composto.
BRPI0907863A2 (pt)	2019-09-24	pirrolopirimidinacarboxamidas
DK2344933T3 (da)	2013-01-14	Uretui
BRPI0909425A2 (pt)	2015-12-01	derivado de hidroxiquinoxalinacarboxamida